Double vs. single high dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area

by Hans E. Johnsen, Bo Björkstrand, Tobias W. Klausen, Kari Remes, Astrid Gruber, Lene M. Knudsen, Olav J. Bergmann, Stig Lenhoff
Published 2009-02-01

Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.

by Martin Boegsted, Johanne M Holst, Kirsten Fogd, Steffen Falgreen, Suzette Sørensen, Alexander Schmitz, Anne Bukh, Hans E Johnsen, Mette Nyegaard, Karen Dybkaer
Published 2011-04-01

Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial

by Hans E. Johnsen, Lene M. Knudsen, Anne K. Mylin, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Niels Frost Andersen, Torben Plesner, Annette Vangsted, Torben Mourits-Andersen
Published 2009-08-01

Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.

by Liesbeth Bieghs, Malene Brohus, Ida B Kristensen, Niels Abildgaard, Martin Bøgsted, Hans E Johnsen, Cheryl A Conover, Elke De Bruyne, Karin Vanderkerken, Michael T Overgaard, Mette Nyegaard
Published 2016-01-01

Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.

by Martin Bøgsted, Anders E Bilgrau, Christopher P Wardell, Uta Bertsch, Alexander Schmitz, Julie S Bødker, Malene K Kjeldsen, Hartmut Goldschmidt, Gareth J Morgan, Karen Dybkaer, Hans E Johnsen
Published 2013-01-01